Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling
Author:
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
http://www.tandfonline.com/doi/pdf/10.4161/mabs.21003
Reference46 articles.
1. Monoclonal antibodies as therapeutic agents for cancer;Harris;Lancet Oncol,2004
2. Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012;4:127rv2. doi: 10.1126/scitranslmed.3001539.
3. Ertumaxomab: a trifunctional antibody for breast cancer treatment;Kiewe;Expert Opin Investig Drugs,2008
4. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer;Kiewe;Clin Cancer Res,2006
5. Cardoso F, Dirix L, Conte PF, Semiglazov V, de Placido S, Jaeger M, et al. Phase II study of single agent trifunctional antibody ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC). San Antonio Breast Cancer Symposium 2010; P3-14-21.
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a‐f;Cancer Science;2023-11-09
2. Biological Therapies in the Treatment of Cancer—Update and New Directions;International Journal of Molecular Sciences;2021-10-28
3. Recombinant immunotoxins development for HER2-based targeted cancer therapies;Cancer Cell International;2021-09-06
4. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo;Frontiers in Immunology;2021-02-17
5. Targeted therapeutic options and future perspectives for HER2-positive breast cancer;Signal Transduction and Targeted Therapy;2019-09-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3